{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:03:25Z","timestamp":1788390205801,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Clomiphene citrate (CC) is often utilized as an adjunct in in vitro fertilization (IVF) protocols during the first 5\u00a0days of stimulation for endogenous FSH release. However, due to its antiestrogenic mechanism of action, CC may also effectively prevent the LH surge, and hence premature ovulation, if continued until the day of trigger. The objective of this study was to evaluate a \u201clong CC\u201d protocol, in which CC is continued throughout the entire cycle in-lieu of GnRH antagonist, and to compare IVF outcomes with a standard 5-day CC\u2009+\u2009GnRH antagonist protocol in patients with diminished ovarian reserve (DOR) undergoing IVF with high-dose gonadotropins.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is a retrospective cohort study of all CC-based IVF cycles at a single institution between 9\/2020 and 9\/2022. Mild stimulation protocols were excluded. The long CC group received CC throughout the entire cycle without GnRH antagonist. The CC\u2009+\u2009GnRH antagonist group received CC for the first 5\u00a0days of stimulation followed by GnRH antagonist when the lead follicle reached 14\u00a0mm. The primary outcome was mature oocyte yield.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There were 361 cycles (77%) in the long CC group and 108 (23%) in the 5-day CC\u2009+\u2009GnRH antagonist group. Age and AMH levels were similar between the two groups. There was no significant difference in mature oocyte yield between the long CC and 5-day CC\u2009+\u2009GnRH antagonist groups (median 5 (IQR 5) vs. 4.5 (IQR 5), respectively, (<jats:italic>P<\/jats:italic>\u2009=\u20090.922)). MII oocytes\/AFC did not differ (0.69 vs. 0.56, respectively, <jats:italic>P<\/jats:italic>\u2009=\u20090.16). Premature ovulation occurred in 0.3% of cycles in the long CC group vs. 3.0% of cycles in the 5-day CC\u2009+\u2009GnRH antagonist group (<jats:italic>P<\/jats:italic>\u2009=\u20090.019).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In DOR patients undergoing IVF, a long CC protocol is an effective and patient-friendly approach associated with non-inferior oocyte yield.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10815-025-03412-w","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:46:01Z","timestamp":1738439161000},"page":"791-797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clomiphene citrate throughout the duration of ovarian stimulation in patients with diminished ovarian reserve: an approach to decrease costs, reduce injection burden, and prevent premature ovulation"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-1462","authenticated-orcid":false,"given":"Rachel S.","family":"Mandelbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Melville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Masjedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Raj-Derouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intira","family":"Sriprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly M.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joie Z.","family":"Guner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"3412_CR1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1126\/science.7221557","volume":"212","author":"AO Trounson","year":"1981","unstructured":"Trounson AO, Leeton JF, Wood C, Webb J, Wood J. Pregnancies in humans by fertilization in vitro and embryo transfer in the controlled ovulatory cycle. Science. 1981;212:681\u20132.","journal-title":"Science"},{"key":"3412_CR2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/jrf.0.0240045","volume":"24","author":"F D\u00f6cke","year":"1971","unstructured":"D\u00f6cke F. Studies on the anti-ovulatory and ovulatory action of clomiphene citrate in the rat. J Reprod Fertil. 1971;24:45\u201354.","journal-title":"J Reprod Fertil"},{"key":"3412_CR3","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0015-0282(16)47832-5","volume":"41","author":"RP Marrs","year":"1984","unstructured":"Marrs RP, Vargyas JM, Shangold GM, Yee B. The effect of time of initiation of clomiphene citrate on multiple follicle development for human in vitro fertilization and embryo replacement procedures. Fertil Steril. 1984;41:682\u20135.","journal-title":"Fertil Steril"},{"key":"3412_CR4","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1210\/endo-82-5-1049","volume":"82","author":"J Kato","year":"1968","unstructured":"Kato J, Kobayashi T, Villec CA. Effect of clomiphene on the uptake of estradiol by the anterior hypothalamus and hypophysis. Endocrinology. 1968;82:1049\u201352.","journal-title":"Endocrinology"},{"key":"3412_CR5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2265.1988.tb03700.x","volume":"29","author":"IE Messinis","year":"1988","unstructured":"Messinis IE, Templeton A. Blockage of the positive feedback effect of oestradiol during prolonged administration of clomiphene citrate to normal women. Clin Endocrinol (Oxf). 1988;29:509\u201316.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"3412_CR6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10815-011-9643-4","volume":"28","author":"VP Jovanovic","year":"2011","unstructured":"Jovanovic VP, Kort DH, Guarnaccia MM, Sauer MV, Lobo RA. Does the addition of clomiphene citrate or letrazole to gonadotropin treatment enhance the oocyte yield in poor responders undergoing IVF? J Assist Reprod Genet. 2011;28:1067\u201372.","journal-title":"J Assist Reprod Genet"},{"key":"3412_CR7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejogrb.2020.05.026","volume":"251","author":"O Triantafyllidou","year":"2020","unstructured":"Triantafyllidou O, Sigalos G, Gkoles L, Kastora S, Vakas P, Batsiou E, et al. The addition of clomiphene citrate to ovarian stimulation protocols for poor responders. Eur J Obstet Gynecol Reprod Biol. 2020;251:136\u201340.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"3412_CR8","first-page":"Cd008528","volume":"11","author":"A Gibreel","year":"2012","unstructured":"Gibreel A, Maheshwari A, Bhattacharya S. Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database Syst Rev. 2012;11:Cd008528.","journal-title":"Cochrane Database Syst Rev"},{"key":"3412_CR9","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.fertnstert.2004.01.022","volume":"81","author":"G D'Amato","year":"2004","unstructured":"D\u2019Amato G, Caroppo E, Pasquadibisceglie A, Carone D, Vitti A, Vizziello GM. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years. Fertil Steril. 2004;81:1572\u20137.","journal-title":"Fertil Steril"},{"key":"3412_CR10","doi-asserted-by":"crossref","first-page":"702558","DOI":"10.3389\/fendo.2021.702558","volume":"12","author":"S Guan","year":"2021","unstructured":"Guan S, Feng Y, Huang Y, Huang J. Progestin-primed ovarian stimulation protocol for patients in assisted reproductive technology: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2021;12:702558.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3412_CR11","first-page":"38","volume":"26","author":"JPJ Caetano","year":"2022","unstructured":"Caetano JPJ, Calazans LC, Amorim LVC, Pereira LMR, Xavier EBS, Campos ALM, et al. Progestin-primed ovarian stimulation is a non-inferior alternative to the GnRH antagonist protocol in patients undergoing assisted reproductive techniques: a retrospective study. JBRA Assist Reprod. 2022;26:38\u201343.","journal-title":"JBRA Assist Reprod"},{"key":"3412_CR12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","volume":"104","author":"Y Kuang","year":"2015","unstructured":"Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104:62-70.e3.","journal-title":"Fertil Steril"},{"key":"3412_CR13","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.fertnstert.2019.07.700","volume":"112","author":"N Pereira","year":"2019","unstructured":"Pereira N, Shah NJ, Kligman I, Rosenwaks Z. Prevention of premature luteinizing hormone surge in poor responders with twice-daily GnRH-antagonist administration. Fertil Steril. 2019;112:e225.","journal-title":"Fertil Steril"},{"key":"3412_CR14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.fertnstert.2014.04.010","volume":"102","author":"DE Reichman","year":"2014","unstructured":"Reichman DE, Zakarin L, Chao K, Meyer L, Davis OK, Rosenwaks Z. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertil Steril. 2014;102:99\u2013102.","journal-title":"Fertil Steril"},{"key":"3412_CR15","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.2147\/DDDT.S338748","volume":"15","author":"Y Lin","year":"2021","unstructured":"Lin Y, Chen Q, Zhu J, Teng Y, Huang X, Chen X. Progestin-primed ovarian stimulation with clomiphene citrate supplementation may be more feasible for young women with diminished ovarian reserve compared with standard progestin-primed ovarian stimulation: a retrospective study. Drug Des Devel Ther. 2021;15:5087\u201397.","journal-title":"Drug Des Devel Ther"},{"key":"3412_CR16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/japtr.JAPTR_293_18","volume":"9","author":"A Zarei","year":"2018","unstructured":"Zarei A, Alborzi S, Askary E, Alborzi M, Shahbazi F. Effects of clomiphene citrate for prevention of premature luteinizing hormone surge in those undergoing intrauterine insemination outcome: a randomized, double-blind, placebo-controlled trial. J Adv Pharm Technol Res. 2018;9:87\u201393.","journal-title":"J Adv Pharm Technol Res"},{"key":"3412_CR17","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.fertnstert.2010.01.069","volume":"94","author":"H Al-Inany","year":"2010","unstructured":"Al-Inany H, Azab H, El-Khayat W, Nada A, El-Khattan E, Abou-Setta AM. The effectiveness of clomiphene citrate in LH surge suppression in women undergoing IUI: a randomized controlled trial. Fertil Steril. 2010;94:2167\u201371.","journal-title":"Fertil Steril"},{"key":"3412_CR18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.mefs.2018.01.005","volume":"23","author":"NM Shams-Eldeen","year":"2018","unstructured":"Shams-Eldeen NM, Shalan HM, Hemida RA-H, Elmetwally A-G. Clomiphene citrate in LH surge suppression for women undergoing ICSI. Middle East Fertil Soc J. 2018;23:281\u20135.","journal-title":"Middle East Fertil Soc J"},{"key":"3412_CR19","doi-asserted-by":"crossref","unstructured":"The Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod 1998;13:3023\u201331.","DOI":"10.1093\/humrep\/13.11.3023"},{"key":"3412_CR20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0015-0282(00)01638-1","volume":"75","author":"M Fluker","year":"2001","unstructured":"Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75:38\u201345.","journal-title":"Fertil Steril"},{"key":"3412_CR21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3389\/fendo.2019.00796","volume":"10","author":"Q Chen","year":"2019","unstructured":"Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X, et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Front Endocrinol (Lausanne). 2019;10:796.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3412_CR22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0015-0282(99)00584-1","volume":"73","author":"EF Branigan","year":"2000","unstructured":"Branigan EF, Estes MA. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression. Fertil Steril. 2000;73:587\u201390.","journal-title":"Fertil Steril"},{"key":"3412_CR23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1472-6483(10)60701-8","volume":"15","author":"S Teramoto","year":"2007","unstructured":"Teramoto S, Kato O. Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study. Reprod Biomed Online. 2007;15:134\u201348.","journal-title":"Reprod Biomed Online"},{"key":"3412_CR24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13048-018-0408-x","volume":"11","author":"H Ochin","year":"2018","unstructured":"Ochin H, Ma X, Wang L, Li X, Song J, Meng Y, et al. Low dose clomiphene citrate as a mild stimulation protocol in women with unsuspected poor in vitro fertilization result can generate more oocytes with optimal cumulative pregnancy rate. J Ovarian Res. 2018;11:37.","journal-title":"J Ovarian Res"},{"key":"3412_CR25","first-page":"119","volume":"7","author":"BI Rose","year":"2015","unstructured":"Rose BI, Laky DC, Rose SD. A comparison of the use of clomiphene citrate and letrozole in patients undergoing IVF with the objective of producing only one or two embryos. Facts Views Vis Obgyn. 2015;7:119\u201326.","journal-title":"Facts Views Vis Obgyn"}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-025-03412-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-025-03412-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-025-03412-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T07:41:57Z","timestamp":1743320517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10815-025-03412-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3412"],"URL":"https:\/\/doi.org\/10.1007\/s10815-025-03412-w","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"USC Institutional Review Board approved (HS-23\u201300039).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}